Levofloxacin (LVFX), a promising, potent, third-generation fluoroquinolone antimicrobial agent, has been extensively investigated in the field of veterinary medicine recently. This study aimed to assess the pharmacokinetic profiles of LVFX in geese after either a single intravenous or oral administration, and to evaluate the depletion profile in tissues – skeletal muscle, heart, liver, kidney, and lung after a single oral dose. A total of 26 clinically healthy geese (Bilgorajska breed) were used in this study. The first group (n=8) received LVFX (2 mg/kg) intravenously, while the second group (n=8) was treated with LVFX orally (5 mg/kg). The tissue depletion study involved 10 geese which were dosed orally (5 mg/kg) and two animals were sacrificed at different time points to collect the selected tissues. LVFX was quantified in all matrices tested by a validated HPLC method with spectrofluorimetric detection. The pharmacokinetics profiles were analysed using a non-compartmental model. LVFX was quantifiable in plasma after up to 24 h in birds administered intravenously and up to 48 h after oral treatment. LVFX was rapidly absorbed after oral administration (Tmax = 0.38 h) showing high bioavailability (96 ± 21%). The average volume of distribution value was 1.40 ± 0.28 L/kg. Plasma clearance was rapid (0.28 ± 0.06 L/kg/h). LVFX residues were highest at 6 h (first collection point) and decreased consequentially until 48 h in the selected tissues. Liver and kidney were found to have the highest drug concentrations. Based on the calculated pharmacokinetic/pharmacodynamic surrogate index - area under the concentration versus time curve divided by the minimal inhibitory concentration (AUC/MIC), the LVFX dosing regimen used in the present study could be effective against bacteria with the MIC < 0.24 μg/mL in geese. In addition, drug accumulation in edible tissues could be controlled using an estimated withdrawal time of 90 h.
- 3.4. Other publications in conference proceedings (including local)